EP 1521588 A2 20050413 - USE OF ALANYL-AMINOPEPTIDASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS
Title (en)
USE OF ALANYL-AMINOPEPTIDASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS
Title (de)
VERWENDUNG VON INHIBITOREN DER ALANYL-AMINOPEPTIDASEN UND DIESE UMFASSENDE PHARMAZEUTISCHEN ZUBEREITUNGEN
Title (fr)
UTILISATION D'INHIBITEURS DES ALANYL-AMINOPEPTIDASES ET PREPARATIONS PHARMACEUTIQUES CONTENANT CES DERNIERS
Publication
Application
Priority
- DE 10230381 A 20020705
- EP 0307199 W 20030704
Abstract (en)
[origin: WO2004004750A2] The invention relates to the use of one or several alanyl-aminopeptidase inhibitors and/or enzyme inhibitors which exhibit the same substrate specificity in order to stimulate the production of TFG-beta 1 and the expression of TFG-beta 1 in and/or on lymphocyte T regulators. The invention also relates to the use of said inhibitors for preventing and/or curing autoimmune, allergic and cardiovascular diseases and to preclude the rejection of transplants. In addition, said invention relates to applications in which peptidic fragments of pathogenic autoantigens or synthetic analogues and/or specific antigenic components of pathogenic microorganisms are used.
IPC 1-7
IPC 8 full level
A61K 45/00 (2006.01); A61K 31/131 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/192 (2006.01); A61K 31/198 (2006.01); A61K 31/401 (2006.01); A61K 31/4035 (2006.01); A61K 31/4164 (2006.01); A61K 31/454 (2006.01); A61K 31/66 (2006.01); A61K 31/661 (2006.01); A61K 31/662 (2006.01); A61K 31/69 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 1/04 (2006.01); A61P 5/16 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP US)
A61K 31/66 (2013.01 - EP US); A61K 38/1709 (2013.01 - EP US); A61P 1/04 (2017.12 - EP); A61P 5/16 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 2004004750A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2004004750 A2 20040115; WO 2004004750 A3 20040506; AU 2003250892 A1 20040123; AU 2003250892 B2 20061116; CA 2490714 A1 20040115; CN 1665524 A 20050907; CN 1665524 B 20100825; DE 10230381 A1 20040122; EA 008946 B1 20071026; EA 200500163 A1 20050825; EP 1521588 A2 20050413; EP 2085094 A2 20090805; JP 2005532380 A 20051027; US 2006211602 A1 20060921; US 7425532 B2 20080916
DOCDB simple family (application)
EP 0307199 W 20030704; AU 2003250892 A 20030704; CA 2490714 A 20030704; CN 03815990 A 20030704; DE 10230381 A 20020705; EA 200500163 A 20030704; EP 03762633 A 20030704; EP 09160281 A 20030704; JP 2004518719 A 20030704; US 52001403 A 20030704